People

Emmanuel Lacroix

PhD, CEO at Neuvasq Emmanuel, ex-Vice President and Partner at UCB Ventures, has an impressive track record of sourcing and leading equity investments in companies like Esobiotec, Walden Biosciences, and Locanabio, as well as LP investments in other funds. As UCB’s Head of Business Development Neurology, he successfully executed multiple licensing agreements, product acquisitions, and equity investments in Lumos Pharma (Nasdaq : LUMO). Emmanuel also led the launch and equity financing of UCB’s spin-out Syndesi Therapeutics, which was later acquired by AbbVie, and held prior leadership positions in Sales and Global Marketing at UCB and in Gene Editing Research at Cellectis SA. Emmanuel received an MBA from IMD (Switzerland), a PhD in Molecular Biology from Université libre de Bruxelles (ULB, Belgium) based on research conducted at the European Molecular Biology Laboratory (Germany), and a MSc in Biochemistry from the Université de Liège (Belgium). He previously served on the boards of Esobiotec, Walden Biosciences, Syndesi Therapeutics (acquired by AbbVie), and as observer at Locanabio and Lumos (Nasdaq : LUMO).